Antidepressants: neither miracle nor menace

Estimated reading time: 3 minutes

Estimated reading time: 6 minutes

A note before we start

This issue steps away from AI to something I get asked about constantly as a psychiatrist. It's educational, not medical advice, and nothing here is a reason to start, stop, or change a medication on your own. Do that with your prescriber.

TL;DR

Welcome to AI-Rx 👋

American psychiatry has spent the past year in the hot seat, with the safety of antidepressants questioned at the highest levels and sensational claims filtering into the press. Some concern is legitimate. A lot is oversimplified.

So this week I'm working through 10 misleading claims about antidepressants, drawn from a clear-eyed commentary by Roger McIntyre and Ronald Pies.

The through-line: these drugs are neither miracle nor menace, and the truth lives in the nuance the headlines strip out.

1. "All antidepressants are the same"

Even the drugs grouped as "SSRIs" aren't purely serotonergic. Sertraline has dopaminergic effects; paroxetine noradrenergic and anticholinergic ones; bupropion has few of the serotonergic side effects like sexual dysfunction or blunting.

That diversity is exactly what lets a good prescriber match a drug to a patient and switch when the first doesn't fit. Much of the "antidepressants" debate is really about one serotonergic subset, generalized to a whole class.

2. "They work by numbing emotions"

Emotional blunting is real, but it's a side effect, not the mechanism.

On the Oxford Depression Questionnaire, successful treatment correlates with less numbing over time, and drugs with minimal blunting risk (bupropion, vortioxetine) are still effective.

Blunting is a problem to manage, not proof the drug is deadening you.

3. "They're just expensive placebos"

A misreading of real data. In Cipriani's meta-analysis of 522 trials and 116,000+ patients, all 21 antidepressants beat placebo, though the average effect was modest.

Two things get ignored: the specific drug benefit reaches an estimated 15-19% of patients, which across ~45 million US users is 7-8.5 million people getting a large improvement; and placebo-arm patients receive 8-12 hours of professional contact, which shrinks the visible gap.

In severe depression, the drug effect becomes distinctly meaningful.

4. "They're addictive"

Antidepressants don't produce the hallmarks of addiction, craving, loss of control, neglecting responsibilities.

On "drug liking" scales, SSRIs score no higher than placebo. The key distinction: withdrawal is not addiction. A drug can be hard to stop without being addictive, and conflating the two frightens patients off treatment for the wrong reason.

5. "They cause suicide"

The debate blurs suicidal thoughts and suicidal behavior.

The black-box warning flags increased suicidal thoughts in under-25s, and may have backfired by reducing appropriate prescriptions.

But in adults 65+, antidepressants are associated with reduced suicidality, and US county data link higher prescribing to lower suicide rates. The picture is age-dependent and demands careful monitoring in young patients, not a blanket claim.

(If you or someone you know is struggling, please reach out to a licensed professional or a crisis line. Help is available.)

6. "They provoke violence and mass shootings"

Careful reviews find no established causal link.

Perpetrators aren't more likely than the public to have been prescribed antidepressants, and most school shooters weren't previously treated. The error is confounding bias: distress can lead both toward treatment and, separately, toward violence.

A shared source isn't proof the treatment caused the harm.

7. "They're vastly overprescribed"

An oversimplification. Direct study found prescribing for mild depression was no more than 18%, far lower than claimed.

Meanwhile only 1 in 5 people with major depression in high-income countries get adequate treatment, there are real racial gaps (13-15% of Black and Asian American respondents with moderate-to-severe symptoms on antidepressants vs 27.3% of White respondents), and only ~29% of US adults screening positive for depression get any treatment.

The real problem is mistargeting, not simple excess.

8. "They mask the root cause and block therapy"

Both halves are shaky. Depression is usually multi-determined, so there's rarely one root to unmask.

And medication versus therapy is a false choice: for moderate-to-severe depression, the combination often beats either alone. Medication is a bridge from feeling depressed to feeling better; therapy is often how the patient walks across it.

For mild-to-moderate cases, the authors recommend talk therapy first.

9. "They cause severe, prolonged withdrawal"

This needs care in both directions.

After accounting for nocebo effects, discontinuation symptoms occur in roughly 15% (about 1 in 6-7 stopping), with severe symptoms far rarer, around 3%. Most are mild and self-limiting, with risk highest for desvenlafaxine, venlafaxine, and paroxetine.

But a minority genuinely do have severe, prolonged withdrawal, and dismissing that invalidates real suffering. The answer is a thoughtful taper over 2-4 months, avoiding short-acting agents, and never stopping on your own.

10. "They don't prevent recurrence long-term"

The myth with the most real uncertainty. Relapse prevention is well established, maintenance can roughly halve relapse risk in high-risk patients.

Recurrence prevention is harder to prove, but the PREVENT study found 2-year recurrence of 28.5% on venlafaxine ER vs 47.3% on placebo, and CANMAT 2023 recommends continuing 2 years or more for at-risk patients. "We lack long-term proof" is not the same as "the drugs don't work long-term."

Here's my final thought

Currently available antidepressants are far from perfect, and the SSRI/SNRI class carries a real side-effect burden. But exaggerated claims of harm have alarmed the public and threatened the substantial group of patients who genuinely benefit.

The goal isn't to defend these drugs or attack them. It's to treat them like any medicine, with honest evidence, careful prescribing, and attention to the patient in front of us.

Medication is a bridge between feeling depressed and feeling better. The patient still has to walk across it, and that's where therapy and self-exploration matter.

Which of these 10 myths do you hear most often, and which one surprised you?

Bhargav Patel, MD, MBA

Physician-Innovator | AI in Healthcare | Child, Adolescent, & Adult Psychiatrist | Medical & AI researcher